🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 15 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 16/02/1995 | 8,25 | 8,38 | 7,88 | 8,38 | +3,88% | 6,06% | 71.400 |
| 15/02/1995 | 7,88 | 8,13 | 7,88 | 8,06 | +0,39% | 3,17% | 108.800 |
| 14/02/1995 | 8,38 | 8,38 | 7,88 | 8,03 | -3,38% | 5,97% | 183.000 |
| 13/02/1995 | 7,88 | 8,38 | 7,88 | 8,31 | +3,10% | 6,35% | 113.200 |
| 10/02/1995 | 8,13 | 8,13 | 7,88 | 8,06 | -0,77% | 3,08% | 23.800 |
| 09/02/1995 | 8,13 | 8,13 | 7,88 | 8,13 | +1,56% | 3,08% | 25.600 |
| 08/02/1995 | 7,88 | 8,13 | 7,75 | 8,00 | +4,07% | 4,76% | 151.000 |
| 07/02/1995 | 7,88 | 7,88 | 7,50 | 7,69 | -0,81% | 4,76% | 108.600 |
| 06/02/1995 | 7,63 | 7,88 | 7,50 | 7,75 | +0,00% | 4,92% | 210.400 |
| 03/02/1995 | 7,75 | 7,75 | 7,50 | 7,75 | +2,48% | 3,23% | 32.200 |
| 02/02/1995 | 7,75 | 7,75 | 7,50 | 7,56 | -0,82% | 3,23% | 104.000 |
| 01/02/1995 | 8,13 | 8,13 | 7,63 | 7,63 | -1,61% | 6,15% | 304.000 |
| 31/01/1995 | 7,63 | 8,13 | 7,63 | 7,75 | +0,81% | 6,56% | 308.000 |
| 30/01/1995 | 7,50 | 8,38 | 7,50 | 7,69 | -3,91% | 11,67% | 255.200 |
| 27/01/1995 | 7,63 | 8,00 | 7,50 | 8,00 | +6,67% | 6,56% | 179.400 |
| 26/01/1995 | 7,25 | 7,75 | 7,13 | 7,50 | +9,09% | 8,62% | 242.400 |
| 25/01/1995 | 6,75 | 7,13 | 6,75 | 6,88 | -5,17% | 5,56% | 50.000 |
| 24/01/1995 | 7,00 | 7,25 | 7,00 | 7,25 | -1,69% | 3,57% | 5.800 |
| 23/01/1995 | 7,13 | 7,38 | 7,00 | 7,38 | +1,72% | 5,26% | 11.400 |
| 20/01/1995 | 7,25 | 7,38 | 6,88 | 7,25 | +5,45% | 6,90% | 150.800 |
| 19/01/1995 | 6,63 | 7,00 | 6,63 | 6,88 | +0,00% | 5,66% | 23.400 |
| 18/01/1995 | 7,25 | 7,25 | 6,69 | 6,88 | -5,17% | 7,76% | 85.800 |
| 17/01/1995 | 7,13 | 7,50 | 7,13 | 7,25 | -0,85% | 5,26% | 80.800 |
| 16/01/1995 | 7,75 | 7,75 | 7,25 | 7,31 | -2,50% | 6,45% | 153.000 |
| 13/01/1995 | 7,75 | 8,13 | 6,50 | 7,50 | -4,76% | 20,97% | 87.800 |
| 12/01/1995 | 7,63 | 8,13 | 7,63 | 7,88 | +3,28% | 6,56% | 32.400 |
| 11/01/1995 | 7,75 | 8,13 | 7,63 | 7,63 | -4,69% | 6,45% | 319.600 |
| 10/01/1995 | 7,63 | 8,13 | 7,50 | 8,00 | +6,89% | 8,20% | 120.400 |
| 09/01/1995 | 7,13 | 7,63 | 7,13 | 7,48 | +1,48% | 7,02% | 76.600 |
| 06/01/1995 | 7,00 | 7,38 | 7,00 | 7,38 | +4,42% | 5,36% | 51.000 |